skip to content

Interim Results

4D Pharma losses widen

28 September 2017 08:13

4D Pharma's pre-tax losses rose to £12.99m in the six months to the end of June - up from £5.5m last time.

Research and development costs increased to £8.3m - up from £4.1m a year ago.

Net assets totalled £75.3m at the end of June compared with £92.1m and £86.5m at the end of 2016. The group had cash and cash equivalents and short-term deposits of £59.8m compared with £75.4m a year ago and £68.8m at the end of December.

Chairman David Norwood said: '2017 has seen 4D continue to make significant progress expanding the scope of our research, developing our manufacturing capability and progressing through the clinic towards our aim of delivering live biotherapeutics in a number of exciting disease areas.'

At 8:13am: (LON:DDDD) 4d Pharma Plc Ord 0.25p share price was -22.5p at 322.5p

Story provided by StockMarketWire.com

Related Company: DDDD

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

-

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.